Type 2 Diabetes Trial, Recruiting (NCT06525259)

Type 2 Diabetes Trial, Recruiting NCT06525259 Sponsor: George Washington University Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT06525259 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children who are overweight or obese, with a BMI at or above the 85th percentile for their age
Girls aged 8 to 13 years, or boys aged 9 to 15 years
Children who are in a middle stage of puberty (Tanner Stage 2, 3, or 4 — the trial site can explain what this means)
Children with a slightly elevated blood sugar level, specifically an HbA1c (a blood test that measures average blood sugar) between 5.5% and 6.4%

Who may not be able to join:

Children who already have a diabetes diagnosis, or whose blood sugar test (HbA1c) has come back at 6.5% or higher
Children or families who are unable or unwilling to give consent or participate fully in the trial
Children with medical conditions that are known to increase the risk of diabetes or affect how puberty develops
Children taking medications that affect blood sugar levels during the screening or enrollment period
Children who have previously been treated with insulin
Children who have used GLP-1 receptor agonist medications (a type of diabetes/weight-loss drug) or any other weight-loss medications in the 6 weeks before enrolling, or who plan to start these medications
Children who have used metformin or other blood sugar-lowering medications for reasons other than treating diabetes (for example, for a condition called PCOS) in the 6 weeks before enrolling, or who plan to start these medications
Children with a known genetic or syndrome-related cause of obesity
Children with blood disorders that can affect the accuracy of the HbA1c blood test, such as certain types of anaemia or haemoglobin variants
Children with serious disease affecting a major organ in the body
Children who have had weight-loss (bariatric) surgery, or who are planning to have it
Children who are currently pregnant or planning to become pregnant
Children currently using certain hormone-related medications, including GnRH agonists, estrogen, or testosterone
Children and families who do not speak English or Spanish, as the questionnaires used in the trial have only been validated in those two languages

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 3018819260

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06525259

Sponsor: George Washington University

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: 3018819260

More information: https://clinicaltrials.gov/study/NCT06525259

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children who are overweight or obese, with a BMI at or above the 85th percentile for their age
Girls aged 8 to 13 years, or boys aged 9 to 15 years
Children who are in a middle stage of puberty (Tanner Stage 2, 3, or 4 — the trial site can explain what this means)
Children with a slightly elevated blood sugar level, specifically an HbA1c (a blood test that measures average blood sugar) between 5.5% and 6.4%

Who may not be able to join:

Children who already have a diabetes diagnosis, or whose blood sugar test (HbA1c) has come back at 6.5% or higher
Children or families who are unable or unwilling to give consent or participate fully in the trial
Children with medical conditions that are known to increase the risk of diabetes or affect how puberty develops
Children taking medications that affect blood sugar levels during the screening or enrollment period
Children who have previously been treated with insulin
Children who have used GLP-1 receptor agonist medications (a type of diabetes/weight-loss drug) or any other weight-loss medications in the 6 weeks before enrolling, or who plan to start these medications
Children who have used metformin or other blood sugar-lowering medications for reasons other than treating diabetes (for example, for a condition called PCOS) in the 6 weeks before enrolling, or who plan to start these medications
Children with a known genetic or syndrome-related cause of obesity
Children with blood disorders that can affect the accuracy of the HbA1c blood test, such as certain types of anaemia or haemoglobin variants
Children with serious disease affecting a major organ in the body
Children who have had weight-loss (bariatric) surgery, or who are planning to have it
Children who are currently pregnant or planning to become pregnant
Children currently using certain hormone-related medications, including GnRH agonists, estrogen, or testosterone
Children and families who do not speak English or Spanish, as the questionnaires used in the trial have only been validated in those two languages

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

George Washington University

Registry

ClinicalTrials.gov

Start date

1 October 2024

Est. completion

31 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Type 2 diabetes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov